Advertisement
BDX vs TMO
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Thermo Fisher Scientific (TMO) boasts stronger year-to-date (YTD) performance at 18.94% compared to Becton, Dickinson and Company (BDX)'s 1.51%.
- BDX offers lower volatility with a beta of 0.28 versus TMO's 0.88 (beta measures a stock's volatility relative to the broader market).
- TMO, with a market cap (market capitalization, total value of outstanding shares) of $174B, dwarfs BDX's $42B, reflecting greater scale in life sciences.
- Both stocks trade at similar trailing price-to-earnings (P/E) ratios around 25, but TMO shows higher earnings per share (EPS, profit allocated per share) at $18.21 versus BDX's $6.12.
- Recent sentiment for BDX reflects caution ahead of earnings amid expected declines, while TMO benefits from expansions like a new bioprocess center.
- Analyst targets suggest upside: 28% for BDX to $191 and 32% for TMO to $620.
Introduction
Becton, Dickinson and Company (BDX) and Thermo Fisher Scientific (TMO) are leading players in the medical technology and life sciences sectors, both providing essential tools for healthcare diagnostics and research. This stock comparison analyzes their recent market positioning, performance trends, and key drivers amid evolving healthcare demands. Investors seeking exposure to defensive medtech stability or growth-oriented biopharma services will find value in understanding their relative strengths, momentum, and risks in the current environment.
BDX Overview and Recent Performance
Becton, Dickinson and Company (BDX) specializes in medical devices, including syringes, catheters, and diagnostic systems, serving hospitals and labs globally. In recent market activity, BDX shares have experienced weakness, trading around $149 with a 52-week range of $128–$187. Year-to-date gains stand at 1.51%, lagging broader indices, influenced by anticipation of softer Q2 results with projected revenue and EPS declines. Sentiment has been tempered by share price pullbacks in recent weeks, though positives include a stable 2.81% dividend yield, innovations in vascular access technology, and employee well-being recognitions. Low beta of 0.28 underscores its defensive profile, appealing in volatile conditions.
TMO Overview and Recent Performance
Thermo Fisher Scientific (TMO) is a diversified giant in scientific instruments, reagents, and bioprocessing services, supporting drug development and research. Shares recently traded near $469, within a 52-week range of $385–$644, reflecting robust YTD performance of 18.94%. Recent weeks saw some volatility, including a post-earnings dip despite Q1 beats on $5.44 adjusted EPS and $11B revenue. Catalysts include a new U.S. bioprocess design center, a $1B sale of its microbiology unit to Astorg, and investor day events, bolstering growth outlook in cell/gene therapy markets. Higher beta of 0.88 signals greater market sensitivity.
Trending AI Robots
Tickeron's Trending AI Robots page features a curated selection of top-performing AI trading bots from over 351 available, which collectively trade thousands of tickers across diverse strategies. Only the most suitable for current conditions—such as volatile tech and sector rotations—earn a spot among the 25 highlighted bots. These showcase impressive stats, including annualized returns ranging from 37% to 97%, win rates of 54–68%, profit factors up to 3.33, and profit-to-drawdown ratios exceeding 17 in some cases. Styles vary from short-term 5-minute scalps to multi-day swings, with risk controls like take-profit/stop-loss corridors. While none currently trend on healthcare tickers like BDX or TMO, Tickeron's full suite covers broad markets. Traders can explore these bots for automated signals tailored to real-time conditions.
Head-to-Head Comparison
BDX focuses on consumable devices with steady demand, contrasting TMO's broader ecosystem of instruments and services tied to R&D cycles. Growth drivers differ: BDX emphasizes patient safety innovations amid margin pressures, while TMO leverages biopharma expansions. Recent momentum favors TMO's YTD edge, though BDX leads one-year returns. Risk profiles highlight BDX's stability (lower beta, reliable dividends) versus TMO's scale-driven upside but higher debt/equity. Both share healthcare exposure, yet TMO benefits from stronger sentiment via strategic deals, while BDX faces earnings headwinds.
Tickeron AI Verdict
Tickeron's AI currently leans toward TMO based on superior YTD momentum, positive catalysts like bioprocessing investments, and elevated analyst targets indicating stronger relative positioning. BDX offers stability but trails in trend consistency amid earnings caution. This probabilistic edge favors TMO for growth-oriented portfolios in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a StrongBuy and TMO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- BDX’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- BDX’s TA Score: 5 bullish, 4 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +4.43% price change this week, while TMO (@Medical Specialties) price change was +3.50% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.05%. For the same industry, the average monthly price growth was +6.39%, and the average quarterly price growth was -4.54%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.03%. For the same industry, the average monthly price growth was +9.32%, and the average quarterly price growth was +10.59%.
Reported Earning Dates
BDX is expected to report earnings on Jul 30, 2026.
TMO is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+3.05% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+3.03% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BDX | TMO | BDX / TMO | |
| Capitalization | 43.6B | 195B | 22% |
| EBITDA | 4.97B | 11.7B | 42% |
| Gain YTD | 4.976 | -9.486 | -52% |
| P/E Ratio | 24.56 | 25.51 | 96% |
| Revenue | 22.2B | 45.2B | 49% |
| Total Cash | N/A | 1.12B | - |
| Total Debt | 17.3B | 43.2B | 40% |
BDX | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 79 | |
SMR RATING 1..100 | 87 | 62 | |
PRICE GROWTH RATING 1..100 | 34 | 49 | |
P/E GROWTH RATING 1..100 | 76 | 43 | |
SEASONALITY SCORE 1..100 | 75 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (5) in the Medical Specialties industry is in the same range as TMO (13). This means that BDX’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (79) in the Medical Specialties industry is in the same range as BDX (100). This means that TMO’s stock grew similarly to BDX’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as BDX (87). This means that TMO’s stock grew similarly to BDX’s over the last 12 months.
BDX's Price Growth Rating (34) in the Medical Specialties industry is in the same range as TMO (49). This means that BDX’s stock grew similarly to TMO’s over the last 12 months.
TMO's P/E Growth Rating (43) in the Medical Specialties industry is somewhat better than the same rating for BDX (76). This means that TMO’s stock grew somewhat faster than BDX’s over the last 12 months.
| BDX | TMO | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 59% |
| Stochastic ODDS (%) | 3 days ago 56% | 3 days ago 63% |
| Momentum ODDS (%) | 3 days ago 50% | 3 days ago 61% |
| MACD ODDS (%) | 3 days ago 46% | 3 days ago 68% |
| TrendWeek ODDS (%) | 3 days ago 46% | 3 days ago 61% |
| TrendMonth ODDS (%) | 3 days ago 48% | 3 days ago 61% |
| Advances ODDS (%) | 3 days ago 43% | 3 days ago 62% |
| Declines ODDS (%) | 5 days ago 43% | 5 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 58% | 3 days ago 60% |
| Aroon ODDS (%) | 4 days ago 36% | 3 days ago 60% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +3.39% | ||
| COO - BDX | 54% Loosely correlated | N/A | ||
| TMO - BDX | 50% Loosely correlated | +1.97% | ||
| BAX - BDX | 48% Loosely correlated | +4.43% | ||
| CNMD - BDX | 48% Loosely correlated | +3.27% | ||
| RVTY - BDX | 45% Loosely correlated | +0.82% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.